Zacks Research Issues Optimistic Outlook for COO Earnings

The Cooper Companies, Inc. (NASDAQ:COO) – Research analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for shares of Cooper Companies in a report issued on Tuesday, December 24th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical device company will earn $1.05 per share for the quarter, up from their previous estimate of $1.04. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ FY2025 earnings at $3.98 EPS, Q1 2026 earnings at $1.02 EPS, Q2 2026 earnings at $1.06 EPS, Q3 2026 earnings at $1.15 EPS, Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.42 EPS and FY2027 earnings at $4.86 EPS.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm’s revenue was up 9.8% compared to the same quarter last year. During the same period last year, the business posted $0.87 earnings per share.

A number of other research analysts have also issued reports on COO. Wells Fargo & Company upped their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Morgan Stanley reduced their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. Robert W. Baird boosted their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Piper Sandler raised their price objective on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $117.00.

Cooper Companies Stock Performance

COO opened at $92.61 on Friday. The firm’s 50-day moving average price is $100.98 and its 200-day moving average price is $98.84. The company has a market cap of $18.48 billion, a P/E ratio of 47.49, a price-to-earnings-growth ratio of 2.52 and a beta of 0.97. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. Cooper Companies has a 52-week low of $84.76 and a 52-week high of $112.38.

Hedge Funds Weigh In On Cooper Companies

Institutional investors have recently made changes to their positions in the company. Mitchell & Pahl Private Wealth LLC grew its position in Cooper Companies by 1.5% during the third quarter. Mitchell & Pahl Private Wealth LLC now owns 7,986 shares of the medical device company’s stock valued at $881,000 after buying an additional 117 shares during the period. Commonwealth Equity Services LLC grew its position in shares of Cooper Companies by 0.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company’s stock valued at $1,362,000 after acquiring an additional 118 shares during the period. Bleakley Financial Group LLC grew its position in shares of Cooper Companies by 2.1% during the 3rd quarter. Bleakley Financial Group LLC now owns 5,767 shares of the medical device company’s stock valued at $636,000 after acquiring an additional 119 shares during the period. Fulton Bank N.A. increased its stake in shares of Cooper Companies by 3.6% in the 3rd quarter. Fulton Bank N.A. now owns 3,609 shares of the medical device company’s stock valued at $398,000 after purchasing an additional 126 shares in the last quarter. Finally, Empirical Finance LLC raised its holdings in Cooper Companies by 2.2% in the 3rd quarter. Empirical Finance LLC now owns 6,786 shares of the medical device company’s stock worth $749,000 after purchasing an additional 145 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.